101
|
Grisanti LA, Talarico JA, Carter RL, Yu JE, Repas AA, Radcliffe SW, Tang HA, Makarewich CA, Houser SR, Tilley DG. β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt. J Mol Cell Cardiol 2014; 72:39-51. [PMID: 24566221 PMCID: PMC4037368 DOI: 10.1016/j.yjmcc.2014.02.009] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2013] [Revised: 01/15/2014] [Accepted: 02/12/2014] [Indexed: 02/03/2023]
Abstract
β-Adrenergic receptor (βAR)-mediated transactivation of epidermal growth factor receptor (EGFR) has been shown to relay pro-survival effects via unknown mechanisms. We hypothesized that acute βAR-mediated EGFR transactivation in the heart promotes differential subcellular activation of ERK1/2 and Akt, promoting cell survival through modulation of apoptosis. C57BL/6 mice underwent acute i.p. injection with isoproterenol (ISO)±AG 1478 (EGFR antagonist) to assess the impact of βAR-mediated EGFR transactivation on the phosphorylation of ERK1/2 (P-ERK1/2) and Akt (P-Akt) in distinct cardiac subcellular fractions. Increased P-ERK1/2 and P-Akt were observed in cytosolic, plasma membrane and nuclear fractions following ISO stimulation. Whereas the P-ERK1/2 response was EGFR-sensitive in all fractions, the P-Akt response was EGFR-sensitive only in the plasma membrane and nucleus, results confirmed in primary rat neonatal cardiomyocytes (RNCM). βAR-mediated EGFR-transactivation also decreased apoptosis in serum-depleted RNCM, as measured via TUNEL as well as caspase 3 activity/cleavage, which were sensitive to the inhibition of either ERK1/2 (PD184352) or Akt (LY-294002) signaling. Caspase 3 activity/cleavage was also sensitive to the inhibition of transcription, which, with an increase in nuclear P-ERK1/2 and P-Akt in response to ISO, suggested that βAR-mediated EGFR transactivation may regulate apoptotic gene transcription. An Apoptosis PCR Array identified tnfsf10 (TRAIL) to be altered by ISO in an EGFR-sensitive manner, results confirmed via RT-PCR and ELISA measurement of both membrane-bound and soluble cardiomyocyte TRAIL levels. βAR-mediated EGFR transactivation induces differential subcellular activation of ERK1/2 and Akt leading to increased cell survival through the modulation of caspase 3 activity and apoptotic gene expression in cardiomyocytes.
Collapse
MESH Headings
- Adrenergic beta-Agonists/pharmacology
- Animals
- Animals, Newborn
- Apoptosis/drug effects
- Apoptosis/genetics
- Caspase 3/genetics
- Caspase 3/metabolism
- Cats
- ErbB Receptors/antagonists & inhibitors
- ErbB Receptors/genetics
- ErbB Receptors/metabolism
- Gene Expression Regulation
- Isoproterenol/pharmacology
- Mice
- Mice, Inbred C57BL
- Mitogen-Activated Protein Kinase 1/genetics
- Mitogen-Activated Protein Kinase 1/metabolism
- Mitogen-Activated Protein Kinase 3/genetics
- Mitogen-Activated Protein Kinase 3/metabolism
- Myocytes, Cardiac/cytology
- Myocytes, Cardiac/drug effects
- Myocytes, Cardiac/metabolism
- Phosphorylation
- Primary Cell Culture
- Proto-Oncogene Proteins c-akt/genetics
- Proto-Oncogene Proteins c-akt/metabolism
- Quinazolines/pharmacology
- Rats
- Rats, Sprague-Dawley
- Receptors, Adrenergic, beta/genetics
- Receptors, Adrenergic, beta/metabolism
- Signal Transduction
- Tyrphostins/pharmacology
Collapse
Affiliation(s)
- Laurel A Grisanti
- Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | - Jennifer A Talarico
- Department of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | - Rhonda L Carter
- Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | - Justine E Yu
- Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | - Ashley A Repas
- Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | - Scott W Radcliffe
- Department of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | - Hoang-Ai Tang
- Department of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | - Catherine A Makarewich
- Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | - Steven R Houser
- Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | - Douglas G Tilley
- Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA.
| |
Collapse
|
103
|
Lakshmikanthan S, Zieba BJ, Ge ZD, Momotani K, Zheng X, Lund H, Artamonov MV, Maas JE, Szabo A, Zhang DX, Auchampach JA, Mattson DL, Somlyo AV, Chrzanowska-Wodnicka M. Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure. Arterioscler Thromb Vasc Biol 2014; 34:1486-94. [PMID: 24790136 DOI: 10.1161/atvbaha.114.303678] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
OBJECTIVE Small GTPase Ras-related protein 1 (Rap1b) controls several basic cellular phenomena, and its deletion in mice leads to several cardiovascular defects, including impaired adhesion of blood cells and defective angiogenesis. We found that Rap1b(-/-) mice develop cardiac hypertrophy and hypertension. Therefore, we examined the function of Rap1b in regulation of blood pressure. APPROACH AND RESULTS Rap1b(-/-) mice developed cardiac hypertrophy and elevated blood pressure, but maintained a normal heart rate. Correcting elevated blood pressure with losartan, an angiotensin II type 1 receptor antagonist, alleviated cardiac hypertrophy in Rap1b(-/-) mice, suggesting a possibility that cardiac hypertrophy develops secondary to hypertension. The indices of renal function and plasma renin activity were normal in Rap1b(-/-) mice. Ex vivo, we examined whether the effect of Rap1b deletion on smooth muscle-mediated vessel contraction and endothelium-dependent vessel dilation, 2 major mechanisms controlling basal vascular tone, was the basis for the hypertension. We found increased contractility on stimulation with a thromboxane analog or angiotensin II or phenylephrine along with increased inhibitory phosphorylation of myosin phosphatase under basal conditions consistent with elevated basal tone and the observed hypertension. Cyclic adenosine monophosphate-dependent relaxation in response to Rap1 activator, Epac, was decreased in vessels from Rap1b(-/-) mice. Defective endothelial release of dilatory nitric oxide in response to elevated blood flow leads to hypertension. We found that nitric oxide-dependent vasodilation was significantly inhibited in Rap1b-deficient vessels. CONCLUSIONS This is the first report to indicate that Rap1b in both smooth muscle and endothelium plays a key role in maintaining blood pressure by controlling normal vascular tone.
Collapse
Affiliation(s)
- Sribalaji Lakshmikanthan
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Bartosz J Zieba
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Zhi-Dong Ge
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Ko Momotani
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Xiaodong Zheng
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Hayley Lund
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Mykhaylo V Artamonov
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Jason E Maas
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Aniko Szabo
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - David X Zhang
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - John A Auchampach
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - David L Mattson
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Avril V Somlyo
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee
| | - Magdalena Chrzanowska-Wodnicka
- From the Blood Research Institute, BloodCenter of Wisconsin, Milwaukee (S.L., M.C.W.); Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville (B.J.Z., K.M., M.V.A., A.V.S.); and Department of Pharmacology and Toxicology (Z.-D.G., J.A.A.), Cardiovascular Center (Z.-D.G., X.Z., J.E.M., D.X.Z., J.A.A.), Department of Medicine (X.Z., J.E.M., D.X.Z.), Department of Physiology (H.L., D.L.M.), and Division of Biostatistics (A.S.), Medical College of Wisconsin, Milwaukee.
| |
Collapse
|
108
|
Curran J, Tang L, Roof SR, Velmurugan S, Millard A, Shonts S, Wang H, Santiago D, Ahmad U, Perryman M, Bers DM, Mohler PJ, Ziolo MT, Shannon TR. Nitric oxide-dependent activation of CaMKII increases diastolic sarcoplasmic reticulum calcium release in cardiac myocytes in response to adrenergic stimulation. PLoS One 2014; 9:e87495. [PMID: 24498331 PMCID: PMC3911966 DOI: 10.1371/journal.pone.0087495] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Accepted: 12/26/2013] [Indexed: 11/19/2022] Open
Abstract
Spontaneous calcium waves in cardiac myocytes are caused by diastolic sarcoplasmic reticulum release (SR Ca(2+) leak) through ryanodine receptors. Beta-adrenergic (β-AR) tone is known to increase this leak through the activation of Ca-calmodulin-dependent protein kinase (CaMKII) and the subsequent phosphorylation of the ryanodine receptor. When β-AR drive is chronic, as observed in heart failure, this CaMKII-dependent effect is exaggerated and becomes potentially arrhythmogenic. Recent evidence has indicated that CaMKII activation can be regulated by cellular oxidizing agents, such as reactive oxygen species. Here, we investigate how the cellular second messenger, nitric oxide, mediates CaMKII activity downstream of the adrenergic signaling cascade and promotes the generation of arrhythmogenic spontaneous Ca(2+) waves in intact cardiomyocytes. Both SCaWs and SR Ca(2+) leak were measured in intact rabbit and mouse ventricular myocytes loaded with the Ca-dependent fluorescent dye, fluo-4. CaMKII activity in vitro and immunoblotting for phosphorylated residues on CaMKII, nitric oxide synthase, and Akt were measured to confirm activity of these enzymes as part of the adrenergic cascade. We demonstrate that stimulation of the β-AR pathway by isoproterenol increased the CaMKII-dependent SR Ca(2+) leak. This increased leak was prevented by inhibition of nitric oxide synthase 1 but not nitric oxide synthase 3. In ventricular myocytes isolated from wild-type mice, isoproterenol stimulation also increased the CaMKII-dependent leak. Critically, in myocytes isolated from nitric oxide synthase 1 knock-out mice this effect is ablated. We show that isoproterenol stimulation leads to an increase in nitric oxide production, and nitric oxide alone is sufficient to activate CaMKII and increase SR Ca(2+) leak. Mechanistically, our data links Akt to nitric oxide synthase 1 activation downstream of β-AR stimulation. Collectively, this evidence supports the hypothesis that CaMKII is regulated by nitric oxide as part of the adrenergic cascade leading to arrhythmogenesis.
Collapse
Affiliation(s)
- Jerry Curran
- Davis Heart and Lung Research Institute, Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, United States of America
| | - Lifei Tang
- Davis Heart and Lung Research Institute, Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, United States of America
| | - Steve R. Roof
- Davis Heart and Lung Research Institute, Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, United States of America
| | - Sathya Velmurugan
- Department of Molecular Biophysics and Physiology, Rush University, Chicago, Illinois, United States of America
| | - Ashley Millard
- Department of Molecular Biophysics and Physiology, Rush University, Chicago, Illinois, United States of America
| | - Stephen Shonts
- Department of Molecular Biophysics and Physiology, Rush University, Chicago, Illinois, United States of America
| | - Honglan Wang
- Davis Heart and Lung Research Institute, Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, United States of America
| | - Demetrio Santiago
- Department of Molecular Biophysics and Physiology, Rush University, Chicago, Illinois, United States of America
| | - Usama Ahmad
- Department of Molecular Biophysics and Physiology, Rush University, Chicago, Illinois, United States of America
| | - Matthew Perryman
- Department of Molecular Biophysics and Physiology, Rush University, Chicago, Illinois, United States of America
| | - Donald M. Bers
- Department of Pharmacology, University of California Davis, Davis, California, United States of America
| | - Peter J. Mohler
- Davis Heart and Lung Research Institute, Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, United States of America
| | - Mark T. Ziolo
- Davis Heart and Lung Research Institute, Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio, United States of America
- * E-mail: (MTZ); (TRS)
| | - Thomas R. Shannon
- Department of Molecular Biophysics and Physiology, Rush University, Chicago, Illinois, United States of America
- * E-mail: (MTZ); (TRS)
| |
Collapse
|